Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective. - Torre E; Di Matteo S; Martinotti C; Bruno GM; Cabrino A; Fogliati EL; Giusti A; Barbieri M; Bottaro LC; Colombo GL (ClinicoEconomics and outcomes research : CEOR, 2026)